CCR8-Targeted Antibody Modulation of Tumor-Infiltrating Tregs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapies for cancer are limited in efficacy due to the suppressive action of regulatory T cells (Tregs) infiltrating tumors, which block immune responses, necessitating a targeted approach to modulate tumor-infiltrating Tregs.
Innovation Solution
Development of anti-CCR8 antibodies that specifically bind to CCR8, inhibiting tumor growth and augmenting antitumor immunity by targeting tumor-infiltrating Tregs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current immunotherapies are used to treat cancer, then some patients show initial responsiveness, but they exhibit relapse following initial response due to suppressive action of tumor-infiltrating Tregs
Solution Approach 1:
The patent extracts and targets the specific problematic component (tumor-infiltrating Tregs expressing CCR8) from the complex tumor microenvironment. By using anti-CCR8 antibodies, the therapy selectively removes or modulates the suppressive Treg population that causes relapse, thereby extending the duration of antitumor immune response while maintaining initial therapeutic efficacy
Solution Approach 2:
The patent applies local quality by targeting CCR8 expression specifically in the tumor microenvironment rather than systemically affecting all Tregs. Since CCR8 is preferentially expressed on tumor-infiltrating Tregs, the antibody therapy selectively modulates the local suppressive population within the tumor, preserving systemic immune function while eliminating the relapse-causing mechanism
2Ease of operation
If current immunotherapies are used to treat cancer, then treatment can be administered, but efficacy is limited due to blockage of immune responses by Tregs
Solution Approach 1:
The patent introduces an intermediary approach by using anti-CCR8 antibodies as a mediator between the administered immunotherapy and the tumor-infiltrating Tregs. The antibody binds to CCR8 on Tregs, blocking their suppressive function and thereby enhancing the efficacy of the co-administered immunotherapy without complicating the administration process
Data Source
AI summary
Disclosed are an anti-CCR8 antibody or antigen-binding portion thereof; a pharmaceutical composition comprising the anti-CCR8 antibody or antigen-binding portion thereof and a pharmaceutically acceptable carrier; a method of treating a disease or condition in a subject in need thereof using the anti-CCR8 antibody or antigen-binding portion or the pharmaceutical composition; and use of the anti-CCR8 antibody or antigen-binding portion thereof in the manufacture of a pharmaceutical for treating a disease or condition.